NCT06626165View on ClinicalTrials.gov

Association Between Effectiveness of Mirikizumab and UC Patients With High Neutrophilic Infiltration in Epithelium of the Colonic Mucosa

PHASE4CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

July 20, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

Ulcerative Colitis

Interventions

DRUG

Mirikizumab

Mirikizmgab will be administered based on the result of Geboes score Grade ≥ 3.2.

DRUG

Vedolizumab

Vedolizmab will be administered based on the result of Geboes score Grade 3.1.

Trial Locations (1)

399-4117

Showa Inan General Hospital, Komagane

All Listed Sponsors

lead

Showa Inan General Hospital

OTHER

NCT06626165 - Association Between Effectiveness of Mirikizumab and UC Patients With High Neutrophilic Infiltration in Epithelium of the Colonic Mucosa | Biotech Hunter | Biotech Hunter